Understanding mechanisms behind metabolic dysfunction-associated steatotic liver disease
Dr. Hirsova's lab seeks to discover the critical cellular and molecular processes underlying pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), and develop targeted therapies for patients with the more inflammatory form of MASLD called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly known as nonalcoholic steatohepatitis (NASH).
Overview
The goals of the Liver Disease Immunobiology Lab led by Petra Hirsova, Pharm.D., Ph.D., at Mayo Clinic are to:
- Dissect the underlying disease mechanisms.
- Identify druggable targets.
- Develop novel therapeutic strategies.
To accomplish these goals, the research team employs a multidisciplinary, translational approach using biologically relevant mouse models, genetic and pharmacological in vivo strategies, as well as pathological human specimens. The laboratory performs a wide range of imaging; molecular, cellular and biochemical techniques; and state-of-the-art methodologies, such as immunophenotyping by mass cytometry, single-cell sequencing and spatial biology.
Affiliations
Dr. Hirsova's Liver Immunobiology Lab is affiliated with these Mayo Clinic research areas: